MetaCap

Milestone Pharmaceuticals (MIST) vs Oncolytics Biotech (ONCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oncolytics Biotech (ONCY) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 65.0% versus a loss of 84.5%. Over five years, ONCY leads with a -80.7% price change compared with -93.8% for MIST. Oncolytics Biotech is the larger company by market cap ($47.7 million vs $46.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MIST-84.54%ONCY-64.99%
+33%-29%-90%
Nov 21, 20251 yearNov 20, 2026
MIST-93.88%ONCY-79.88%
+84%-9%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MIST versus ONCY key metrics
MetricMISTONCY
Share price$0.3711$0.3501
Market cap$46.20M$47.66M
1-day change-7.06%-10.37%
YTD return-81.63%-59.76%
1-year return-84.54%-64.99%
5-year return-93.85%-80.66%
EPS (TTM)$-0.74$-0.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-63.06M$-28.76M
52-week high$3.06$1.30
52-week low$0.362$0.33
Distance from 52-week high-87.87%-73.07%
Analyst consensusnonebuy
Avg. price target upside+1479.09%+1085.38%
Average volume1.53M1.17M
Shares outstanding124.50M136.14M
Employees3829
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ONCY has outperformed MIST by 19.5 percentage points over the past year.

About Milestone Pharmaceuticals

MIST stock →

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Oncolytics Biotech

ONCY stock →

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

MIST vs ONCY FAQ

Which is bigger, Milestone Pharmaceuticals or Oncolytics Biotech?

Oncolytics Biotech (ONCY) is larger, with a market capitalization of $47.66M compared with $46.20M for Milestone Pharmaceuticals (MIST).

Which stock has performed better over the past year, MIST or ONCY?

ONCY returned -64.99% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.

Are Milestone Pharmaceuticals and Oncolytics Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons